Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 君实生物 |
|---|---|
| Other Market Stock Code | 688180 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Junshi Bio |
|---|---|
| Stock Code | 01877 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 創新驅動型生物製藥公司,致力於創新藥物的發現和開發,以及全球臨床研究及商業化。利用蛋白質工程核心平台技術,專注腫瘤免疫療法、自身免疫性疾病及代謝疾病治療,擁有多項在研生物藥品。 |
| Listing Date | 2018-12-24 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國(上海)自由貿易試驗區蔡倫路781號602室 |
| Business Address (Hong Kong) | 香港皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | junshipharma.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 19.38 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2018-12-11 to 2018-12-14 |
| Global Offering Shares | 158,910,000 shares |
| HK Public Offer Shares (Initial) | 15,892,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 143,018,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 760,310,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 61.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 3,079,675,800 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 5.03B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 亏损人民幣321.1百萬元 |
| Period-End Cash Balance | 人民幣266.3百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 | 2017 | 2018-06 |
|---|---|---|---|
| Revenue | 3,757 | 1,148 | |
| Cost of sales | -986 | -446 | |
| Gross profit | 2,771 | 702 | |
| Other income and gains, net | 16,409 | 52,342 | 2,635 |
| Administrative expenses | -42,760 | -73,752 | -49,792 |
| Net finance costs | -2,439 | ||
| Share of associates and JVs | 31 | -3 | |
| Profit before tax | -131,249 | -320,744 | -272,977 |
| Income tax expense | -241 | -58 | 70 |
| Profit for the year | -131,967 | -321,071 | -272,760 |
| Profit attributable to owners | -131,020 | -320,844 | -272,786 |
Balance Sheet
| Item | 2016 | 2017 | 2018-06 |
|---|---|---|---|
| Cash and cash equivalents | 111,387 | 266,298 | 391,919 |
| Trade and bills receivables | 514 | 220 | |
| Inventories | 7,086 | 30,603 | 46,887 |
| Total equity | 1,126,615 | 1,119,334 | 1,153,797 |
| Equity attributable to owners | 1,127,562 | 1,120,508 | 1,154,945 |
| Interest-bearing borrowings | 0 | 0 | 229,687 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018-06 |
|---|---|---|---|
| Net cash from operating activities | -185,207 | -347,076 | -263,626 |
| Net cash from investing activities | -717,176 | 187,712 | -130,100 |
| Net cash from financing activities | 646,286 | 319,634 | 514,489 |
| Net increase in cash | -256,097 | 160,270 | 120,763 |
| Depreciation of PP&E | 842 | 165 | 631 |
| Purchase of PP&E | -199,789 | -263,721 | -189,714 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 23.75 |
|---|---|
| First Day Open | HK$ 23.5 |
| First Day Change | 22.55% |
| First Day Volume | 18500500.0 |
| First Day Turnover | 431273000.0 |
| Use of Proceeds | 1、約40%或1177.60百萬港元的所得款項凈額將用于研發及商業化核心產品JS001,為JS001的臨床試驗提供資金;
2、約16%或471.04百萬港元的所得款項凈額將用于研發其他在研藥品,為臨床試驗提供資金;
3、約9%或264.96百萬港元的所得款項凈額將用于興建臨港生產基地及吳江生產基地;
4、約25%或736.00百萬港元的所得款項凈額將用于投資及收購制藥行業的公司,特別是具有與本公司互補的強大研發及/或商業化能力的公司;
5、約10%或294.40百萬港元的所得款項凈額將用作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (4)
Joint Bookrunners (6)
Joint Lead Managers (6)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Highbury Investment Pte Ltd | 352,522,200 HKD | — | 11.45% | — | 6 months | 2019-06-24 |
| 2 | Loyal Valley Capital Advantage Fund LP | 720,722,820 HKD | — | 23.40% | — | 6 months | 2019-06-24 |
| 3 | Megastar Investment Management Limited | 117,500,940 HKD | — | 3.82% | — | 6 months | 2019-06-24 |
| 4 | TR Capital III, L.P. | 23,488,560 HKD | — | 0.76% | — | 6 months | 2019-06-24 |
| 5 | 北京鼎联鑫科技发展有限公司 | 164,516,820 HKD | — | 5.34% | — | 6 months | 2019-06-24 |
| 6 | 王树君 | 258,509,820 HKD | — | 8.39% | — | 6 months | 2019-06-24 |
| 7 | 俞建午 | 258,509,820 HKD | — | 8.39% | — | 6 months | 2019-06-24 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 熊俊 | — |
| Company Secretary | 陳英格、袁頴欣 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 熊鳳祥(直接持股9.74%)、熊俊(直接持股8.37%)、上海檀英(持股9.78%)、蘇州瑞源(直接持股7.25%)為主要股東;一致行動人士合計持股約22.04%。 |
|---|




